Trial Profile
A retrospective trial to evaluate potential relationship between homozygous deletion of PTEN and outcomes for EGFR-mutant non-small cell lung cancer patients treated with gefitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 02 Feb 2016 New trial record